Q3 2024 Medpace Holdings Inc Earnings Call Transcript
Key Points
- Revenue for the third quarter of 2024 was $533.3 million, representing a year-over-year increase of 8.3%.
- EBITDA for the third quarter increased by 31.7% compared to the same period in 2023, reaching $118.8 million.
- Net income for the third quarter rose by 36.7% year-over-year, driven by interest income and partially offset by a higher effective tax rate.
- Ending backlog as of September 30, 2024, was approximately $2.9 billion, an increase of 8.8% from the prior year.
- The company expects to convert approximately $1.62 billion of backlog into revenue over the next 12 months, indicating strong future revenue potential.
- Backlog cancellations in Q3 were above the usual range, marking three consecutive quarters of elevated cancellations.
- Net new business awards decreased by 12.7% from the prior year, resulting in a net book-to-bill ratio of 1.0 for the quarter.
- The elevated cancellations are expected to depress reported net backlog awards in Q4 and Q1 of 2025.
- RFPs were down modestly on a year-over-year and sequential basis, indicating a potential slowdown in new business opportunities.
- Gross bookings were lower in the quarter due to prior cancellations, impacting the overall business momentum.
Good day, ladies and gentlemen and welcome to the Medpace third quarter 2024 earnings conference call (Operator Instructions) As a reminder, this call may be recorded.
I would now like to introduce your host for today's conference call. Lauren Morris, Medpace's Director of Investor Relations. You may be begin.
Good morning and thank you for joining Medpace's third quarter 2024 earnings conference call. Also on the call today is our CEO, August Troendle; our President, Jesse Geiger; and our CFO, Kevin Brady. Before we begin, I would like to remind you that our remarks and responses to your questions during this teleconference may include forward-looking statements within the meaning of the Private Security Litigation Reform Act of 1995.
These statements involve inherent assumptions with known and unknown risks and uncertainties as well as other important factors that could cause actual results to differ materially from our current expectations. These factors are discussed in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
